

India's Sun Pharma inks new deal to commercialise skin cancer drug in Europe, Australia and New Zealand

31 May 2023 | News

Sun Pharma and Philogen enter into an exclusive distribution, license, and supply agreement



India-based Sun Pharmaceutical Industries and Swiss-Italian biotech firm Philogen S.p.A have entered into a licensing agreement for commercialising Philogen's specialty product, Nidlegly (Daromun) in the territories of Europe, Australia and New Zealand.

Nidlegly, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical which is being developed by Philogen for the treatment of melanoma and non-melanoma skin cancers.

Under the terms of the agreement, Sun Pharma will have exclusive rights to commercialise Nidlegly for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe, pursue Marketing Authorisation with the regulatory authorities and manufacture commercial supplies.

Sun Pharma will be responsible for commercialisation activities. The two partner companies will share post-commercialisation economics in about 50:50 ratio. Other financial terms were not disclosed. Philogen will retain the IP rights for Nidlegly for other territories and indications other than skin cancers.

Nidlegly is a biopharmaceutical product, proprietary to Philogen, designed for the treatment of skin cancer. It consists of two active ingredients, L19IL2 and L19TNF which are manufactured independently, and which are mixed prior to intralesional administration.